Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, and OneThree Biotech, a company redesigning drug discovery with biology-driven artificial intelligence, announced their collaboration and the successful completion of a study focused on the identification of specific biomarkers for new indications in targeted oncology patient populations.
As part of the collaboration, Jubilant Therapeutics sought to determine the mechanism for its potentially first-in-class dual epigenetic inhibitor targeting melanoma, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) and select solid tumor subsets. Utilizing the OneThree Biotech platform, they were able to:
- Generate new data to support the dual inhibition (LSD1 and HDAC6) to drive inhibition
- Pinpoint molecular markers that could be used to identify patients who might benefit from the dual inhibition
- Determine additional target indications for future trials
“The convergence of biology and scalable data science is enabling new approaches to de-risk early-stage programs through biomarker discovery and patient selection,” said Syed Kazmi, President and CEO of Jubilant Therapeutics. “Jubilant Therapeutics has a strong biomarker-driven innovation platform and we are pleased to collaborate with OneThree Biotech in the application of their proven biology-driven AI approach to streamline the delivery of right medicines to right patients who may not be currently benefiting from available cancer therapies.”
“We’ve been incredibly impressed with Jubilant Therapeutics’ approach of combining focused experimentation with mechanistic biology and how they have re-thought the drug development process through the inclusion of new technology like AI. We’ve seen how results from this partnership can shape downstream clinical development and are excited to see it continue to evolve.” said Neel S. Madhukar, PhD, co-founder and CEO of OneThree Biotech.
A challenge in traditional drug development is generating an understanding of the biological mechanisms that drive the efficacy of a small molecule compound. OneThree Biotech has built an AI-powered platform that integrates over 40 data types to understand these underlying mechanisms and how they link drugs, targets and patients. This comprehensive approach enables delivery of informed insights to biopharma partners at critical stages of the development process.
JBI-802 is currently being evaluated in IND-enabling studies for the treatment of hematological and select solid tumors with specific gene signatures and first-in-human clinical studies are expected in 2021. Jubilant Therapeutics Inc. is developing a pipeline of novel, differentiated therapeutic assets.